The big medical news of 2026 is about the big blockbuster drug of 2025. Semaglutide (a.k.a. Ozempic, a.k.a. Wegovy) is now off patent in Canada. In the U.S. and the rest of the world, patent ...
Major domestic pharma companies are witnessing pricing pressure in the generics segment in the US, their largest export market. Many of them are trying to address this by focusing more on high-value ...
The Food and Drug Administration (FDA) approved a generic version of the abortion pill mifepristone in October, making chemical abortion more affordable and accessible to pregnant women who wish to ...
Advocacy groups form a buyer’s club to obtain generic versions of pricey Vertex cystic fibrosis drug
Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...
Abstract: Mobile Crowdsensing (MCS) has become a popular sensing paradigm, where a number of participants use their mobile devices to collectively share and extract information related to a certain ...
Dr. Reddy’s Laboratories (NYSE:RDY) is preparing to launch a generic version of semaglutide, the active ingredient in Novo Nordisk’s (NVO) weight loss drug Wegovy, in 87 countries beginning in 2026, ...
HYDERABAD, July 16 (Reuters) - Biocon (BION.NS), opens new tab aims to launch generic copies of the blockbuster weight-loss drug Wegovy in India and Canada within the next two years, a top executive ...
INDIANAPOLIS — When you are out shopping, you often see labels showing where the product is made. But look at your generic medication and there is a good chance the "made in" line is missing. Dr.
A U.S. appeals court has lifted a temporary halt it imposed on the launch of a generic version of Novartis's (NYSE:NVS) top-selling cardiac drug Entresto. The U.S. Court of Appeals for the District of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results